Orbit develop and apply innovative drug discovery platforms defined by a unique peptide display engine that deliver novel, functional, biologically relevant peptide therapeutic leads.
The Orbit peptide display engine is uniquely able to address cell-based targets and thereby screen targets in relevant contexts.
Peptide leads are key starting points for the development of peptide, peptidomimetic and small molecule therapeutics as well as bioconjugates for cell targeting and cargo delivery.
Founded in late 2015 as a spin-out from Oxford University based on the work of Professors Graham Ogg and Terry Rabbitts. We have a pipeline of novel targets in in-house programmes and we work in collaboration with others in industry and academia to make our technology as accessible as possible.
The Orbit peptide display engine is uniquely able to address cell-based targets and thereby screen targets in relevant contexts.
Peptide leads are key starting points for the development of peptide, peptidomimetic and small molecule therapeutics as well as bioconjugates for cell targeting and cargo delivery.
Founded in late 2015 as a spin-out from Oxford University based on the work of Professors Graham Ogg and Terry Rabbitts. We have a pipeline of novel targets in in-house programmes and we work in collaboration with others in industry and academia to make our technology as accessible as possible.
Location: United Kingdom, England, Oxford
Employees: 11-50
Total raised: $16.82M
Founded date: 2015
Investors 4
| Date | Name | Website |
| - | Oxford Uni... | innovation... |
| - | Oxford Inv... | oxfordinve... |
| - | Perivoli I... | perivoliin... |
| - | Oxford Sci... | oxfordscie... |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 20.07.2021 | - | $7.6M | - |
| 23.05.2018 | Series A | $9.22M | - |
Mentions in press and media 10
| Date | Title | Description |
| 03.12.2024 | Orbit Discovery and Evergreen Theragnostics expand research collaboration to advance targeted therapeutics development | Oxford, UK, and Springfield, NJ, USA, 3rd December 2024: Orbit Discovery, a leading provider of peptide discovery services, and Evergreen Theragnostics, a radiopharmaceutical company at the forefront of precision medicine, today announced a... |
| 28.05.2024 | Secarna Pharmaceuticals and Orbit Discovery enter collaboration to discover and develop peptide-conjugated targeted antisense oligonucleotide therapeutics | Partnership expands spectrum of Secarna’s capabilities for the development of targeted ASOs beyond antibodies and sugar molecules New platform capabilities extend the reach of Secarna’s antisense approaches, potentially offering new treatme... |
| 07.03.2022 | Orbit Discovery and WuXi AppTec sign agreement to access peptide discovery and optimisation technologies | Orbit Discovery and WuXi AppTec sign agreement to access peptide discovery and optimisation technologies 07-03-2022 Oxford, United Kingdom, Orbit Discovery (Orbit), a ground-breaking peptide discovery company, announces the commencement of ... |
| 21.07.2021 | Orbit Discovery Raises $7.6M in Funding | Orbit Discovery, an Oxford, England, UK-based biopharmaceutical company focused on discovering candidate peptide therapeutics harnessing proprietary affinity and cell-based functional screening platforms, raised $7.6m (USD) in funding. The ... |
| 20.07.2021 | Orbit Discovery announces $7.6 million funding to accelerate growth in peptide discovery business | Orbit Discovery announces $7.6 million funding to accelerate growth in peptide discovery business 20-07-2021 Oxford...Orbit Discovery Ltd, a privately held biopharmaceutical company focused on discovering candidate peptide therapeutics harn... |
| 20.07.2021 | Orbit Discovery announces $7.6 million funding to accelerate growth in peptide discovery business | Oxford...Orbit Discovery Ltd, a privately held biopharmaceutical company focused on discovering candidate peptide therapeutics harnessing proprietary affinity and cell-based functional screening platforms, today announced that it has raised... |
| 20.07.2021 | Orbit Discovery : Announces $7.6 Million Funding to Accelerate Growth in Peptide Discovery Business | Orbit Discovery Ltd., (“Orbit”), a privately held biopharmaceutical company focused on discovering candidate peptide therapeutics harnessing proprietary affinity and cell-based functional screening platforms, today announced that it has rai... |
| 29.06.2021 | Orbit Discovery appoints Dr Neil Butt as Chief Executive Officer | Orbit Discovery appoints Dr Neil Butt as Chief Executive Officer 29-06-2021 Oxford, UK, June 29, 2021: Orbit Discovery Ltd, a biopharmaceutical company focused on discovering candidate peptide therapeutics using high throughput microfluidic... |
| 23.05.2018 | Peptide Display Company Orbit Discovery Raises £6.9M in Series A Financing | Orbit Discovery Ltd, an Oxford, UK-based biotech company developing a peptide identification and optimization platform, closed a £6.9M Series A financing. The round was led by Oxford Sciences Innovation with participation from new investors... |
| 23.05.2018 | Term Sheet — Wednesday, May 23 | 5 Qs WITH A DEALMAKER Good morning, Term Sheet readers. Paid Content You can't secure what you can't see From ExtraHop “When I looked around, I saw a lot of women who were starting businesses,” she told Term Sheet. “I recognized that in the... |